TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride with Hypofractionated Re-Irradiation Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (GBM)
What is the purpose of this trial?
This is a dose-escalation study that will assess the safety and determine the maximum tolerated dose (MTD) of mibefradil dihydrochloride, a partially selective T-type calcium channel blocker, combined with hypofractionated radiation therapy (RT) in subjects with recurrent glioblastoma multiforme (GBM).
- Yale Cancer Center
- Last Updated:
- Study HIC#: